MRSA

SHEA has released expert guidance advising hospitals on when they can safely take patients with multidrug-resistant bacteria off of contact precautions.

Maureen Spencer, Accelerate Diagnostics, sat down with Contagion® to discuss the challenges of disinfecting hospital rooms to prevent C. difficile.

At this year’s annual CHEST meeting, Theravance Biopharma investigators report positive new data pertaining to VIBATIV gleaned from the TOUR study.

Proton pumps inhibitors present risks for individuals living with HIV, dalbavancin can treat MRSA-related pneumonia, probiotics prove deadly against C. difficile, patient involvement increases healthcare practitioners’ hand hygiene, and why delafloxacin is a unique antibiotic for skin infections are the topics that make up this week’s Top 5 articles.

Researchers from the University of Mississippi report a case of an HIV-positive man with pneumonia due to MRSA who was treated with dalbavancin.

What's the best recipe for MRSA screening and isolation practices?

The results of a new study show that antibiotic treatment may help improve recovery for minor skin abscesses.

An infection control intervention coming from the VHA resulted in a significant reduction of MRSA in veteran living centers.

Contagion® sat down with Rodrigo Mendes, PhD, to discuss research exploring evolving resistance among antibiotics to treat skin infections.

Jerod Nagel, PharmD, highlights how rapid diagnostic tools can be utilized in antibiotic stewardship programs to improve outcomes for patients with S. aureus.

Researchers from Montefiore Medical Center presented findings on differential diagnosis of MRSA and Staphylococcus aureus at the 2017 Annual Pediatric Academic Societies (PAS) meeting in San Francisco, California.

An outbreak of MRSA at a Los Angeles-area hospital’s neonatal intensive care unit has raised questions about when health officials were notified of the outbreak, and why the public was not informed sooner.

Researchers collected biofilms from several hospitals in four non-neighboring countries to determine if the persistence of multidrug-resistant organisms in biofilms on hospital surfaces was a worldwide problem.

At the SHEA Spring 2017 Conference, Laurie Conway, RN, PhD, CIC, provided conference goers with options that will allow them to “pick their battles” when it comes to ensuring effective surveillance targets.

Robin Jump, MD, PhD, discussed the challenges associated with isolation precautions in long-term care settings, specifically nursing homes during her presentation at the SHEA Spring 2017 Conference on March 30, 2017.

On March 30, 2017, at the SHEA Spring 2017 Conference, Thomas Sandora, MD, MPH, shared some tips regarding ways to manage movement outside of the room for patients who are on contact precautions.

Contagion® will be covering the conference, and so keep a look out for session coverage, as well as interviews with some of the key presenters.

A multi-institution research team has found that daptomycin is effective and well-tolerated in children.

Duke Health researchers have found that a UVC machine use can reduce transmission of harmful superbugs in hospital settings.

Contagion® takes a closer look at how Staphylococcus aureus infections continue to plague professional sports players.

Daniel Pilch, PhD, associate professor in the Department of Pharmacology at Rutgers Robert Wood Johnson Medical School, co-founder of TAXIS Pharmaceuticals, and co-author of the study, explains the bactericidal behavior of TXA709, a new drug to treat MRSA infections.

Edmond LaVoie, PhD, professor and chair, Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers University, co-founder of TAXIS Pharmaceuticals, and co-author of the study on the new MRSA drug, TXA709, explains how TXA709 targets MRSA differently than other antibiotics.

Edmond LaVoie, PhD, professor and chair, Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, co-founder of TAXIS Pharmaceuticals, and co-author of the study on the new MRSA drug, TXA709, discusses the social and economic implications of methicillin-resistant Staphylococcus aureus.

Daniel Pilch, PhD, associate professor in the Department of Pharmacology at Rutgers Robert Wood Johnson Medical School, co-founder of TAXIS Pharmaceuticals, and co-author of the study, explains why MRSA is especially dangerous, and the effectiveness of the team’s new drug, TXA079.

An initiative from the Veterans Health Administration to reduce methicillin resistant Staphylococcus aureus (MRSA) and other healthcare-associated infections in the facilities has led to marked infection reduction around the country.

Michael D. Nailor, PharmD, BCPS-AQ ID, clinical associate professor at the University of Connecticut School of Pharmacy, clinical specialist in infectious diseases at Hartford Hospital, and director of Infectious Disease Residency program at Hartford Hospital, discusses which skin and soft tissue infections (SSTIs) are likely to be drug-resistant.

University of Connecticut researchers have developed novel antibiotic compounds to target methicillin-resistant Staphylococcus aureus infections, offering a potential new drug in the fight against this pathogen.

A new study has characterized risk factors for the development of active methicillin-resistant Staphylococcus aureus (MRSA) among patients who are colonized with the bacteria at hospital admission.

Emergency room providers are misdiagnosing too many patients with cellulitis, according to a new study, causing unnecessary hospitalizations and inappropriate antibiotic use.